| Literature DB >> 11476839 |
S Tsiodras, H S Gold, G Sakoulas, G M Eliopoulos, C Wennersten, L Venkataraman, R C Moellering, M J Ferraro.
Abstract
The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11476839 DOI: 10.1016/S0140-6736(01)05410-1
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321